Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Date
2023-12-31Author
Gregucci, F
Spada, S
Barcellos-Hoff, MH
Bhardwaj, N
Chan Wah Hak, C
Fiorentino, A
Guha, C
Guzman, ML
Harrington, K
Herrera, FG
Honeychurch, J
Hong, T
Iturri, L
Jaffee, E
Karam, SD
Knott, SRV
Koumenis, C
Lyden, D
Marciscano, AE
Melcher, A
Mondini, M
Mondino, A
Morris, ZS
Pitroda, S
Quezada, SA
Santambrogio, L
Shiao, S
Stagg, J
Telarovic, I
Timmerman, R
Vozenin, M-C
Weichselbaum, R
Welsh, J
Wilkins, A
Xu, C
Zappasodi, R
Zou, W
Bobard, A
Demaria, S
Galluzzi, L
Deutsch, E
Formenti, SC
Type
Journal Article
Metadata
Show full item recordAbstract
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
Collections
Subject
FLASH radiotherapy
dose and fractionation
immune checkpoint inhibitors
immunomodulators
lymph node sparing
tumor-associated macrophages
Humans
Combined Modality Therapy
Neoplasms
Immunotherapy
Research team
Trans Immunotherapy
Targeted Therapy
Language
eng
Date accepted
2023-06-02
License start date
2023-12-31
Citation
OncoImmunology, 2023, 12 (1), pp. 2222560 -
Publisher
TAYLOR & FRANCIS INC